The Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry, valued at US$ 638.96 Million in 2023, is set to experience unprecedented growth, reaching a staggering US$ 1598 Million by the year 2033. This impressive trajectory is driven by a robust Compound Annual Growth Rate (CAGR) of 9.6% between 2023 an.